INVESTORS & MEDIA

Press Releases

Year

Precision BioSciences Announces Dosing of First Patient in Off-The-Shelf CAR T Cell Therapy Phase 1/2a Clinical Trial

April 17, 2019

First NHL patient treated with allogeneic CAR T in U.S.-based trial DURHAM, N.C. , April 17, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS ® genome editing platform, announced...

Precision BioSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

April 1, 2019

DURHAM, N.C. , April 01, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome editing platform, today announced the closing of its initial public offering of 9,085,000 shares of...

Precision BioSciences Announces Pricing of Initial Public Offering

March 27, 2019

DURHAM, N.C. , March 27, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome editing platform, today announced the pricing of its initial public offering of 7,900,000 shares of...

Raymond Schinazi Joins Precision BioSciences Board of Directors

March 14, 2019

DURHAM, North Carolina, USA, March 14, 2019 – Precision BioSciences (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome editing platform, has appointed Raymond Schinazi, PhD, Hon DSc to its board of directors. Dr....

Precision BioSciences Enters Into Private Convertible Note Financing

March 9, 2019

DURHAM, North Carolina, USA, March 16, 2019 – Precision BioSciences (“Precision” or the “Company”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome editing platform, today announced that it has entered into an agreement for the issuance and sale of...

Elo Life Systems Announces a Collaboration With Ashland Subsidiary Avoca to Scale a Sustainable, Key Input for Fragrances

February 25, 2019

DURHAM, NORTH CAROLINA – February 25, 2019 – Elo Life Systems Inc. announced today a collaboration with Avoca LLC, a subsidiary of the specialty chemicals company Ashland, that is focused on improving the production of Clary Sage plants and a related compound called Sclareol....

Precision BioSciences Announces Formation of Scientific Advisory Board With Anderson, Kantarjian, Schinazi and Turtle

January 16, 2019

DURHAM, North Carolina, USA, January 16, 2019 – Precision BioSciences today announced the formation of its Scientific Advisory Board (SAB) with four key appointments: Kenneth C. Anderson, MD, Hagop Kantarjian, MD, Raymond Schinazi, PhD, DSc, and Cameron Turtle, MBBS, PhD. Drs....

INVESTORS & MEDIA

Overview
Corporate Governance
Press Releases
Events & Presentations
Stock Information
SEC Filings
Investor FAQs

Investor Tools

Print Page
Email Page
Email Alerts
Document Request
Contact IR
RSS Feeds

INVESTORS & MEDIA

Press Releases

Press Releases

INVESTORS & MEDIA

Investor Tools

Contact Info

919.314.5512

About Us

Quick Links

Legal